Do amyloid β-associated factors co-deposit with Aβ in mouse models for Alzheimer's disease?
Senile plaques and cerebral amyloid angiopathy in Alzheimer's disease (AD) patients not only consist of the amyloid-β protein (Aβ), but also contain many different Aβ-associated factors, such as heparan sulfate proteoglycans, apolipoproteins, and complement factors. These factors may all influence Aβ deposition, aggregation, and clearance and therefore seem important in the development of human Aβ deposits. To study AD pathology and test new therapeutic agents, many different mouse models have been created. By transgenic expression of the amyloid-β protein precursor, frequently in combination with other transgenes, these animals develop Aβ deposits that morphologically resemble their human counterparts. Whether this resemblance also applies to the presence of Aβ-associated factors is largely unclear. In this review, the co-deposition of factors known to associate with human Aβ deposits is summarized for several different AD mouse models.
Timmer
Nienke M
NM
Department of Neurology, Department of Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Alzheimer Centre Nijmegen, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. n.timmer@neuro.umcn.nl
Kuiperij
H Bea
HB
de Waal
Robert M W
RM
Verbeek
Marcel M
MM
D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D001053:Apolipoproteins / Q000378:metabolism*; D003165:Complement System Proteins / Q000378:metabolism*; D004195:Disease Models, Animal; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism*; D006801:Humans; D051379:Mice
D016229:Amyloid beta-Peptides; D001053:Apolipoproteins; D019812:Heparan Sulfate Proteoglycans; D003165:Complement System Proteins